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Abstract Desmogleins (DSG) are a family of cadherin
adhesion proteins that were first identified in desmosomes
and provide cardiomyocytes and epithelial cells with the
junctional stability to tolerate mechanical stress. However,
one member of this family, DSG2, is emerging as a protein
with additional biological functions on a broader range of
cells. Here we reveal that DSG2 is expressed by non-
desmosome-forming human endothelial progenitor cells as
well as their mature counterparts [endothelial cells (ECs)]
in human tissue from healthy individuals and cancer
patients. Analysis of normal blood and bone marrow
showed that DSG2 is also expressed by CD34?CD45dim
hematopoietic progenitor cells. An inability to detect other
desmosomal components, i.e., DSG1, DSG3 and desmo-
collin (DSC)2/3, on these cells supports a solitary role for
DSG2 outside of desmosomes. Functionally, we show that
CD34?CD45dimDSG2? progenitor cells are multi-potent
and pro-angiogenic in vitro. Using a ‘knockout-first’
approach, we generated a Dsg2 loss-of-function strain of
mice (Dsg2lo/lo) and observed that, in response to reduced
levels of Dsg2: (i) CD31? ECs in the pancreas are hyper-
trophic and exhibit altered morphology, (ii) bone marrow-
derived endothelial colony formation is impaired, (iii)
ex vivo vascular sprouting from aortic rings is reduced, and
(iv) vessel formation in vitro and in vivo is attenuated.
Finally, knockdown of DSG2 in a human bone marrow EC
line reveals a reduction in an in vitro angiogenesis assay as
well as relocalisation of actin and VE-cadherin away from
the cell junctions, reduced cell–cell adhesion and increased
invasive properties by these cells. In summary, we have
identified DSG2 expression in distinct progenitor cell
subpopulations and show that, independent from its clas-
sical function as a component of desmosomes, this cad-
herin also plays a critical role in the vasculature.
Keywords DESMOGLEIN-2  Endothelial progenitor
cells  Endothelium  Hematopoietic stem and progenitor
cells  Mouse models of neoangiogenesis
Introduction
Desmoglein-2 (DSG2), a type 1 transmembrane protein
belonging to the cadherin family, is an adhesion molecule
with well-described functions in the formation of cell–cell
adhesion complexes called desmosomes. The desmosome is
a specialised junction that provides intercellular links giving
tensile strength to tissues that experience mechanical stress,
such as in the myocardium, skin and gastrointestinal mucosa
[1–3]. These complex, transversely symmetrical structures
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are composed of the transmembrane spanning cadherins,
which interact via homotypic and/or heterotypic combina-
tions to form the adhesive interface between cells, together
with the intracellular proteins plakoglobin, desmoplakin and
plakophilin which link the junction to the intermediate fil-
ament cytoskeleton. In humans, four desmoglein isoforms
(DSG1-4) and three desmocollin isoforms (DSC1-3) have
been identified, which are temporo-spatially expressed [4].
DSG2 is expressed in all desmosome-bearing tissues,
including cardiac muscle, whereas distribution of other
isoforms is confined primarily to stratified epithelial tissue
[1–3]. In keeping with its role in tissue integrity, loss of
DSG2 function in humans is directly linked to arrhythmo-
genic right ventricular cardiomyopathy (ARVC), an auto-
somal recessive disease underpinned by myocyte apoptosis
and fibrous degeneration of the myocardium [5, 6].
In the context of tissue remodelling, the identification of
endothelial progenitor cells (EPCs) has significant clinical
implications for the repair processes of wound healing [7],
limb ischaemia [8] and myocardial ischaemia [9, 10].
Reduced numbers of circulating EPCs are commonly
observed in pathological conditions such as diabetes and
cardiovascular disease [11–14]. Despite ongoing controver-
sies regarding the nature and role of EPCs in vasculogenesis
[12, 15–18], the ability of human EPCs to rescue diminished
blood flow in a number of animal models [19, 20] provided a
rationale for clinical trials of EPC infusion therapy in
humans. Pre-clinical studies found infusion of CD34? and
CD133? EPCs to be safe and beneficial, but the effects of
EPCs in humans were less robust [12]. Nevertheless, since
the discovery of EPCs [21], significant steps forward have
been taken to better define and functionally characterise
these cells, and in the light of the enormous therapeutic
potential of modulating vasculogenesis in disease, efforts
continue to better understand their origin, plasticity and role
in the vasculature.
In this study, we reveal that DSG2 expression and
function extend beyond myocardial cells and the epithe-
lium to hematopoietic stem and progenitor cells (HSPCs),
EPCs and some mature endothelium but not mature
hematopoietic cells. Through functional studies, we
demonstrate that DSG2? EPCs are pro-angiogenic, and the
generation of a Dsg2 loss-of-function strain of mice has
revealed that this surface-expressed cadherin regulates EC
morphology and is important for vascular sprouting and
colony formation ex vivo, as well as vessel formation
in vivo. Moreover, we demonstrate that despite ECs being
a non-desmosome-forming cell, reduction of DSG2 on
these cells significantly impacts on their cell–cell adhesive
capacity which is likely via reduced DSG2–DSG2 homo-
typic interactions. Taken together, we provide novel
insights into an underappreciated role for DSG2 in
hematopoietic cells and the vasculature.
Materials and methods
Ethics statement
The collection of primary human umbilical vein endothe-
lial cells (HUVEC), mononuclear cells (MNC) from buffy
coats or freshly collected peripheral blood, human mes-
enchymal stromal cells, gingival and periodontal stem
cells, healthy donor peripheral blood, bone marrow, normal
tissue as well as cancerous tissue was approved by the
Human Research Ethics Committee of the Royal Adelaide
Hospital (RAH), Adelaide, South Australia. The collection
of primary human umbilical cord blood (UCB) was
approved by the Human Research Ethics Committee of the
Children, Youth and Women’s Health Service (CYWHS),
North Adelaide, South Australia. Animal experiments were
approved by the Animal Ethics Committees of SA
Pathology and the Peter MacCallum Cancer Centre (pro-
tocol E526) and conformed to the guidelines established by
the ‘Australian Code of Practice for the Care and Use of
Animals for Scientific Purposes’.
Isolation and culture of UCB CD1331 non-adherent
endothelial forming cells (naEFCs)
UCB (20–130 ml) was obtained from healthy pregnant
women undergoing elective caesarean section and col-
lected into MacoPharma cord blood collection bags
(MSC1201DU; MacoPharma, Mouvaux, France). CD133?
cells were isolated prior to naEFC cell culture using pub-
lished methods [22].
Peripheral blood MNCs, human umbilical vein
endothelial cells (HUVEC), bone marrow
endothelial cells (BMEC) and normal human bone
marrow
Peripheral blood from healthy individuals was collected in
lithium heparin coated Vacuette tubes (Greiner Bio-One,
Kremsmuenster, Austria) or was provided as buffy coats
from the Australian Red Cross Blood Service. For most
experiments, MNCs were isolated using Lymphoprep.
However, for analysis of VEGFR2? EPCs, whole blood
was subjected to erythrocyte lysis using PharmLyse (BD,
Franklin Lakes, NJ, USA) followed by depletion of mature
leucocytes using the Lineage Cell Depletion kit (Miltenyi
Biotec, Bergisch Gladbach, Germany) according to the
manufacturer’s instructions. Primary HUVEC were
extracted from human umbilical veins by collagenase
digestion and cultured in HUVE medium as previously
described [23, 24] and were used for no more than two
passages. Human bone marrow endothelial cells
(TrHBMEC) were a kind gift from B Weksler (Cornell
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University Medical College, NY, USA) [25, 26] and
hereafter labelled as BMEC. Normal human bone marrow
samples were pre-filtered through a 70-lm nylon filter (BD
Falcon) to remove debris and then subject to red blood cell
lysis using PharmLyse (BD) according to the manufac-
turer’s instructions prior to flow cytometric staining and
analysis.
Induced pluripotent, dental pulp and mesenchymal
stem cells
Bone marrow-derived human mesenchymal stem cells
(Merck Millipore, NSW, Aust.) were cultured as per
manufacturers’ instructions. Induced pluripotent stem (iPS)
cells were generated and confirmed for pluripotency as
previously described [27]. Similarly, dental pulp stem cells
(DPSCs) were isolated from dental pulp tissue and enzy-
matically digested as per previous instructions [28].
Flow cytometric analysis of cell surface protein
expression
Staining was performed in complete RF-10 medium
(RPMI ? 10 % FCS) with cells (\1 9 106) blocked with
1 mg/ml human IgG, incubated with unconjugated mAbs
(Online resource Supp. Table 1), washed and incubated
with secondary antibody. After washing, 5 ll of normal
mouse serum was added and conjugated mAbs were then
added to the cells. After washing, cells were fixed in 1 %
formaldehyde, 20 g/l glucose, 5 mM sodium azide in PBS
(‘FACS-Fix’), prior to analysis using either an Accuri C6
Cytometer (BD) or Gallios Flow Cytometer (Beckman
Coulter, Brea, CA, USA). Further analysis was performed
using FCS Express 4 Flow Cytometry: Research Edition
(De Novo Software, CA, USA).
DSG21 cell enrichment by flow cytometric sorting
and expansion
DSG2? cells were isolated from UCB or fresh bone mar-
row (BM)-derived MNCs using a FACSAria II (BD).
MNCs were co-stained with anti-DSG2, anti-CD34-PerCP-
Cy5.5 and anti-CD45-FITC. Within the CD34?CD45dim
population, the DSG2? and DSG2- cells were identified
and sorted by FACS, with the sorting gate position based
on the fluorescence-minus-one (FMO) control. Immedi-
ately following isolation, a small portion of the sorted cells
was re-analysed on the FACSAriaTM II (BD) to assess
purity. Sorted DSG2? and DSG2- cells were cultured in
EPC expansion CellGro media (CellGenix, Freiburg, Ger-
many) as previously described [29].
Detection of human DSG2 mRNA using quantitative
polymerase chain reaction (qPCR)
Quantification of mRNA levels was carried out using
qPCR. Primers were designed for human DSG2 (F-50-
CCATTGCGGAAAGGGCGCCA-30, R-50-GGCAGAAAT
GATGGCACCACCTTGT-30) using Primer Blast (NIH,
MD, USA) and purchased from GeneWorks (Hindmarsh,
SA, Aust.). Quantitative PCR amplification was performed
using QuantiTectTM SYBR Green master mix (QIAGEN,
Hilden, Germany) on a Rotor-Gene thermocycler (Corbett
Research, Mortlake, NSW, Aus.) with reaction parameters:
15 min at 95 C, then cycling of 10 s 95 C, 20 s 55 C
and 30 s 72 C; for 45 cycles followed by a melt phase.
Resultant data were analysed using Rotor-Gene Analysis
Software version 6 (Corbett Research). Relative gene
expression levels were calculated using standard curves
generated by serial dilutions of cDNAs normalised to the
human house-keeping gene cyclophilin A (CycA) (F-50GG
CAAATGCTGGACCCAACACAAA-30, R-50CTAGGCA
TGGGAGGGAACAAGGAA30).
Hematopoietic colony formation assay
Freshly isolated DSG2? naEFCs (±expansion) (*1800
DSG2?/- sorted and expanded cells/well or *500 freshly
sorted cells/well) were plated in methylcellulose and cul-
tured with growth factors as previously described [22] with
hematopoietic colonies scored after 14 days.
Generation of the Dsg2 ‘loss-of-function’ mouse
strain
The pipeline for the design and construction of the Dsg2
‘loss-of-function’ mouse strain was based on the publica-
tion by Skarnes et al. [30]. Briefly, the CSD (Children’s
Hospital Oakland Research Institute/Wellcome Trust San-
ger Institute/University of California at Davis) approach
incorporates a promoter-driven targeting cassette for the
generation of a ‘knockout-first allele’ wherein loxP and
FRT sites are placed in introns of genes of interest [30].
More specifically for this study, this ‘gene trap’ approach
utilised a targeted insertion of a FRT-flanked lacZ-neo-
mycin cassette into intron 1 of the murine Dsg2 locus of in
embryonic stem (ES) cells (i.e., clone EPD0156_5_E04;
EuMMCR, Neuherberg, Germany). The Dsg2tma1 strain
of mice were generated via ES cell microinjection into
Balb/c blastocysts to generate chimeric mice which were
then confirmed to be heterozygous for insertion of the lacZ-
neomycin construct prior to being inter-bred bred for germ
line transmission using C57Bl/6 N mice at the Australian
Phenomics Network (APN, Melbourne, Vic. Aust.). These
mice yielded fertile wildtype (WT), heterozygous and
Angiogenesis (2016) 19:463–486 465
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homozygous offspring at the expected Mendelian ratios
(1:2:1), with litter sizes similar to WT C57BL/6N controls.
Detection of murine Dsg2: genomic DNA and mRNA
Genomic DNA was extracted from mouse-tail tips using a
REDExtract-N-Amp Tissue PCR Kit (Sigma-Aldrich, St.
Louis, MO, USA) prior to genotype confirmation via PCR
with reaction parameters as follows: 2 min at 94 C, then
cycling of 30 s at 94 C, 30 s at 61 C and 45 s at 72 C;
for 35 cycles followed by 4 C. The following primers
were used to determine WT, heterozygous and homozy-
gous Dsg2tma1 genotypes; P1: 50CTGCTGCAACTTGAT
GTCC30, P2: 50GAAAGGCGGTTCTGTAATTCC30 and
P3: 50CAACGGGTTCTTCTGTTAGTCC30.
Total RNA was extracted from hearts and skin harvested
from C57Bl/6 wildtype (WT), Dsg2tma1 heterozygous and
homozygous mice. Hearts were homogenised in Trizol
prior to chloroform extraction. The aqueous layer con-
taining the RNA was then isolated and 70 % ethanol added
before completing the extraction method using an RNEasy
Mini Kit (QIAGEN). 0.5–1 lg of total RNA was converted
into first-strand cDNA using Superscript III reverse tran-
scriptase (Life Technologies, Carlsbad, CA, USA) fol-
lowing the manufacturer’s instructions.
Dsg2 gene knockdown was validated by qPCR using
primers designed to span an intron/exon border between
exons 14 and 15 (F-50AACGAAGCCGTAAGGACAAG30
R-50GCCGCTTTCTCTGTGAAGTA30) via Primer Blast,
and purchased from GeneWorks. qPCR amplification was
performed using QuantiTectTM SYBR Green master mix
(QIAGEN) on a Rotor-Gene thermocycler (Corbett
Research) with reaction parameters: 15 min at 95 C, then
cycling of 10 s 95 C, 20 s 55 C and 30 s 72 C; for 45
cycles followed by a melt phase. Data obtained were
analysed using Rotor-Gene Analysis Software version 6
(Corbett Research). Relative gene expression levels were
calculated by normalising to the mouse house-keeping
gene hprt (F-50CCCAGCGTCGTGATTAGCG30) (R-
50GCA CACAGAGGGCCACAATG30) using geNorm
software [31].
Immunohistochemistry and immunofluorescence
Mouse hearts were fixed in PBS containing 4 %
formaldehyde, washed and embedded in paraffin; 4-lm-
thick tissue sections were cut and stained with Mayer’s
hematoxylin and eosin staining (H&E) (Dako Agilent
Technologies, Glostrup, Denmark).
Tissue microarray (TMA) slides were purchased from
BioChain (Newark, CA, USA). Slides were dewaxed and
rehydrated prior to pressure cooker antigen retrieval in
10 mM citrate buffer (pH 6) for 20 min. After cooling to
30 C, the sections were incubated for 60 min at room
temperature with primary mAb directed against DSG2
(1:50 dilution; clone 3G132; Abcam) or an isotype-mat-
ched negative control. The polymer system ADVANCE
HRP (Dako Australia Pty Ltd, Vic., Australia) employing
DAB as the detection system was used for detection of
primary mAb binding. Counterstaining was performed
using Mayer’s hematoxylin.
Immunofluorescence microscopy was performed on
paraffin-embedded human cervical sections with heat
mediated antigen retrieval in 10 mM citrate buffer (pH 6.5)
incubated overnight at 4 C with a primary antibody
against DSG2 (2 lg/ml, clone 6D8, Invitrogen, Carlsbad,
CA, USA) or CD31 (2 lg/ml, pAb, Bethyl Laboratories,
Montgomery, TX, USA). Sections were washed and sec-
ondary antibodies (goat anti-mouse Alexa fluor-594 (1:500,
Abcam, Cambridge, UK) or goat anti-rabbit Alexa Fluor-
488 (1:500, Abcam) applied for 1 h at RT prior to washing
and mounting in ProLong Gold with DAPI (Life Tech-
nologies). Sections were analysed using an Olympus
CV1000 spinning disk microscope and integrated software.
For whole mount staining of adult mouse ear skin, ears
were fixed in 4 % paraformaldehyde overnight at 4 C.
Skin was then peeled away from cartilage and incubated in
blocking solution (PBS containing 1 % BSA and 0.3 %
Triton X-100) overnight at 4 C. Following blocking, ear
skin samples were incubated with rat anti-CD31 (BioLe-
gend, San Diego, CA, USA), rabbit anti-LYVE-1 (Angio-
bio, Del Mar, CA, USA) and Cy3-conjugated anti-SMA
(Sigma-Aldrich) diluted in blocking solution overnight at
4 C and were then washed extensively in PBS-0.1 %
Triton X-100 (6 9 1 h) at 4 C. Ear skin samples were
then incubated with Alexa Fluor-conjugated secondary
antibodies (Invitrogen) overnight at 4 C and washed as
outlined above. Samples were mounted using DAPI
FLUOROMOUNTTM G (ProSciTech). Images were cap-
tured using a Zeiss LSM 700 confocal microscope (Zeiss
Laboratories, Jena, Germany) and a Zeiss inverted Axio
Observer Z1 fluorescence microscope.
For immunofluorescence staining of mouse pancreases,
mice were humanely killed via cervical dislocation and the
whole pancreas was removed. Pancreases were washed in
cold phosphate buffered saline (PBS; Life Technologies)
and fixed in 4 % paraformaldehyde (Chem Cruz, Santa
Cruz Biotechnology Inc., Dallas, TX, USA). They were
then embedded in OCT (TissueTek, Sakura Finetek, Tor-
rance, CA, USA), frozen using dry ice and cut into 5-lm-
thin sections using a cryostat (CM1520, Leica Biosystems,
North Ryde, NSW, Aust.). Frozen sections were probed
with primary antibodies: rat anti-mouse CD31 (Biolegend),
Cy-3-conjugated anti-SMA (Sigma-Aldrich) or isotype
control of rat IgG (Abcam) followed by goat anti-rat Alexa
466 Angiogenesis (2016) 19:463–486
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Fluor-488 or -594 (Life Technologies). DAPI Pro-long
gold anti-fade mounting medium (Life Technologies) was
used for nuclear staining and mounting with images cap-
tured using a Zeiss LSM710 multiphoton or Olympus IX71
(Olympus Corporation, Tokyo, Japan) fluorescence
microscope.
Immunofluorescence of siRNA-KD BMEC cells was
undertaken by fixing cells in either 2 % paraformaldehyde
or cold 1:1 acetone:methanol (for DSG2) 72 h post-trans-
fection. After 5 % goat serum blocking, cell-containing
coverslips were labelled overnight with the following
mouse monoclonal antibodies: VE-cadherin (1:50; clone
F-8-Santa Cruz Biotechnology) and DSG2 (1:50; clone
6D8-Thermo Fisher). Primary antibody binding was
detected using 1:500 goat anti-mouse IgG conjugated to
AlexaFluor 488. To label F-actin filaments, cells were
incubated with 1:1000 Phalloidin-Rhodamine (Thermo
Fisher) for an hour. Coverslips were mounted on glass
slides in Prolong Gold Antifade Reagent with DAPI
(Thermo Fisher). Images were captured using Olympus
CV1000 with a 409 objective, and analysis of VE-cadherin
staining was undertaken using an ImageJ macro. Staining
was split into respective channels, i.e., blue (nuclei) and
green (VE-cadherin). This macro-determined the total
positive areas and number of nuclei per image. Results
were presented as the total fluorescence area over nuclei
count. To characterise cell phenotypes of DSG2-KD cells,
phalloidin staining was analysed in a randomised and
blinded manner. Cells were categorised and counted as
either cortical actin (circumferential) or stress fibre (mild to
extensive actin network) and the percentage was deter-
mined and averaged for each siRNA and control. In addi-
tion, Image J was used to determine the localisation of VE-
cadherin protein via pixel intensity as previously described
[34].
Matrigel tube formation assay: in vitro
In vitro angiogenesis assay of HUVEC and DSG2?
sorted cells was performed using a Matrigel matrix as
previously described [29]. Briefly, cells were seeded
together on a layer of Matrigel (In vitro Technologies,
Noble Park, Vic., Aust.) at a cell density of 1.7 9 104
HUVEC, with or without 1.0 9 104 DSG2? sorted cells/
well, in duplicate. Similarly, the BMEC cells were see-
ded at 1.5 9 104 cells per well in triplicate. Images
covering the entire well were captured after 5–6 h using
an inverted imaging microscope (EVOS XL, Life tech-
nologies), merged using Adobe Photoshop and tube-like
structures manually counted using Image J software
(1.47v, NIH, Bethesda, MD, USA).
Matrigel plug assay: in vivo
Female Dsg2?/? (wildtype, WT) and Dsg2lo/lo mice were
used between 6 and 8 weeks of age and housed in specific
pathogen-free conditions in the SA Pathology Animal Care
Facility with Matrigel plug assays conducted as previously
described [29]. Briefly, 500 ll of Matrigel containing 2 lg/
ml basic fibroblast growth factor (R&D Systems, Min-
neapolis, MN, USA) and 50 units/ml heparin (Sigma-
Aldrich) were injected subcutaneously into both flanks of
6–8 week-old mice. Mice were humanely killed by cervical
dislocation on day 7 post-injection and Matrigel plugs
removed, washed in PBS, fixed in 4 % paraformaldehyde
(VWR International, Radnor, PA, USA) overnight, embed-
ded in paraffin, cut into 8 lm sections on a microtome (RM
2235 Leica, Solms, Germany) and placed onto slides
(Polysine, Menzel-Gla¨ser, Thermo Scientific). The sections
were stained for CD31? ECs (goat anti-mouse/human
CD31, Santa Cruz, Dallas, TX) with biotinylated rabbit anti-
goat secondary (Abcam), followed by Vectastain elite ABC
regent (Vector Labs, Burlingame, CA, USA) for DAB
staining as per manufacturer’s instructions and hematoxylin
counterstaining. Negative controls included isotype-matched
irrelevant antibodies. Images of sections were collected
using a Hamamatsu Nanozoomer slide scanner with ery-
throcyte-containing CD31? vessels counted manually and
section areas quantified using the NDPview software (Ha-
mamatsu Photonics, Hamamatsu, Japan).
Mouse endothelial cell colony-forming assay
Using published methods, whole BM cells were flushed
from femurs and tibiae of Dsg2?/? and Dsg2lo/lo mice and
adherent EC colony units were defined as a cell mass
composed of a central cord of round cells with elongated
spindle-shaped cells sprouting at the periphery [32].
Aortic ring assay
The aortic ring assay was performed on thoracic aorta-
derived rings from 12- to 14 week-old Dsg2?/? or Dsg2lo/lo
mice as described [33] where aortic rings were observed
over a period of 6 days without or with VEGF (30 ng/ml)
added at day three. Aortic sprouts were stained with rat anti-
CD31 (BioLegend) and goat anti-rat Alexa Fluor-594 (Life
Technologies) to confirm endothelialisation, captured by a
Zeiss LSM 700 confocal microscope (Zeiss Laboratories,
109 obj) and quantitated using phase-contrast microscopy
via an inverted IX70 microscope 4x/0.13NA obj, an S15 F
view camera and Analysis Life Sciences software (Olym-
pus). Number of rings quantitated per group was 3–4.
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B16 melanoma mouse model
To evaluate CD31? vessels in tumours, 1.4 9 104 B16
mouse melanoma cells were injected into the right flanks of
age-matched, syngeneic (C57Bl/6 N) Dsg2?/? (WT) and
Dsg2lo/lo mice and resultant tumours harvested at endpoint.
Sections were cut from FFPE-stored tumour tissues and
labelled with anti-CD31 antibody (BD Biosciences). Sec-
ondary detection was performed using biotinylated anti-rat-
Ig, streptavidin-conjugated horse-radish peroxidase and
3-amino-9-ethylcarbazole chromogen. Stained sections
were scanned using an Olympus VS120 scanner and
CD31? blood vessels were counted in each field to obtain
an average number of CD31 ? blood vessels per field.
DSG2 gene knockdown using siRNA
‘Trilencer-27’ siRNA duplexes targeting human DSG2
were purchased from Origene Technologies (Rockville,
MD, USA). Transfection was performed using Lipofec-
tamine RNAiMax (Thermo Fisher) according to the man-
ufacturer’s protocol, using a final concentration of 10 nM
for both DSG2-targeting and control siRNAs. On the basis
of time course experiments, BMEC cells were used in
experiments 72 h after knockdown where DSG2 knock-
down efficiency was routinely assessed by flow cytometry.
Cell viability was assessed by incubating the cells with
annexin V-FITC (1:50 in 1x binding buffer; BD Bio-
science) for 15 min at RT prior to incubation with 7-AAD
(BD Biosciences) for 5 min at 4 C. Stained cells were
then resuspended in FACS-Fix and analysed by flow
cytometry as described above.
EC cell adhesion assay
BMEC (±DSG2-targeting or control siRNA) transfected
48 h prior were cultured at 1 9 106 cells/35 mm 9 10 mm
dish (Corning, Sigma-Aldrich) to form a confluent mono-
layer. Twenty-four hours later, 0.5 9 106 of 72 h-trans-
fected BMEC (±DSG2-targeting or control siRNA) were
labelled with 0.5 lM Calcein-AM (eBiosciences, San
Diego, CA, USA) and incubated on top of the confluent
monolayer for 15 min after which time the non-adherent
cells were washed with Hanks Balanced Salt Solution
(HBSS, Sigma-Aldrich) using a parallel plate flow chamber
system (GlycoTech Corporation, Gaithersburg, MD, USA)
with a flow rate of 0.156 ml/min for 2 min. Fluorescently
labelled adherent cells were imaged using an inverted
epifluorescence microscope Olympus IX71 and a 49/0.10
objective. Adherent cells were quantified using ImageJ in a
blinded and randomised manner.
Inverse invasion assay
Adapted from Hennigan et al. [35], 100 ll of growth fac-
tor-reduced Matrigel diluted 1:1 in cold PBS was added
into an 8.0-lm-pore-sized Transwell (Corning Incorpo-
rated) and allowed to set. Transwells were then inverted,
and 3000 siRNA-transfected (at 24 h) BMEC were seeded
onto the underside of the membrane. Four hours later, the
unbound cells were rinsed and Transwells immersed right-
















































Fig. 1 DSG2 expression by human naEFCs (EPCs). In a, DSG2
mRNA expression in UCB-derived CD133? human naEFCs and
HUVECs was determined by qPCR and expression values are shown
as mean ± SEM, n = 3–4, * p\ 0.05. In b, evaluation by flow
cytometry of DSG2 protein expression (solid line) on EPCs. Dotted
line shows isotype control. c Immunofluorescence evaluation of
DSG2 protein expression on EPCs (middle, scale bar is 5 lm) and
HaCat cells (right, scale bar is 20 lm). Isotype control (iso) staining
on EPCs (left). EPC stainings in b–c are representative of results from
C3 independent EPC donors
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10 % serum was added to the upper chamber as
chemoattractant, and cells allowed to migrate upward into
the Matrigel for 96 h. Transwells were paraformaldehyde
fixed, RNAse-treated (100 lg/ml, Affymetrix USB) and
stained with 0.05 mg/ml of Propidium Iodide (Thermo
Fisher), and all steps were carried out for 30 min with two
PBS washes between each. Transwells were imaged at
fixed intervals (6.68 lm) starting at the membrane and in a
direction towards the chemoattractant using z-stack setting
of Zeiss LSM 700 confocal microscope with a 109
objective. Cells from 3 fields of view per slice of distance
travelled were quantified using ImageJ and then averaged.
Statistical analysis
Results were expressed as mean ± standard error of the
mean (SEM) from at least 3 experiments. Unless otherwise
stated, an unpaired Student’s t test, 1- or 2-way ANOVA
for multiple comparisons, was performed to determine
statistical significance between groups with p values\0.05
considered significant.
Results
Human endothelial progenitor cells (EPCs) express
desmoglein (DSG)-2
In a global comparative gene expression analysis of human
umbilical cord blood (UCB)-derived CD133?CD34?-
VEGFR2? non-adherent endothelial progenitor cells
(EPCs) and donor matched HUVECs, we identified DSG2
to be significantly elevated in EPCs (NCBI Gene Expres-




DSG1-BV421 DSG3-BV421 DSC2/3-BV421  
FMO control VEGFR2 staining
p = 0.08
C
Fig. 2 Unique expression of DSG2, but not other desmosome
components, on circulating progenitor cells including EPCs. In a,
lineage-depleted peripheral blood was analysed by flow cytometry for
co-expression of DSG2 and VEGFR2. The gating strategy involved
initial selection of cells based on physical parameters (FSC/SSC; left),
followed by gating of the CD34? CD45dim progenitor population
(centre), within which staining for DSG2 in combination with either
control IgG (FMO [fluorescence-minus-one] control) or anti-
VEGFR2 was determined. Results are representative of 4 donors. In
b, the proportion of DSG2? cells was compared for peripheral and
umbilical cord blood samples, gating on CD34? CD45dim progenitor
cells as shown above. c UCB samples were analysed by flow
cytometry for expression of the indicated desmosomal cadherins,
gating on CD34?CD45dim progenitor cells, in comparison with
isotype control. Results are representative of 3 donors
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Validation by qRT-PCR in additional donors confirmed
that EPCs express *180-fold more DSG2 mRNA when
compared to HUVEC (Fig. 1a). Subsequent flow cyto-
metric analysis confirmed surface expression of DSG2 by
EPCs (Fig. 1b) with immunofluorescence microscopy
revealing a diffuse distribution of DSG2 over the cell
surface and through the cytoplasm (Fig. 1c). This pattern
of expression is unusual for desmosomal cadherins, which
normally exhibit punctate distribution in desmosome-
forming cells such as the HaCat keratinocytes (Fig. 1c).
As these particular non-adherent EPCs are derived fol-
lowing 4 days of ex vivo culture [22], we also evaluated
the expression of DSG2 on freshly isolated EPCs; that is,
the small subpopulation of circulating CD34? progenitor
cells that co-express VEGFR2 [36, 37]. In progenitor-en-
riched peripheral blood from healthy donors, we used flow
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cytometric analysis to identify a small subset of VEGFR2?
cells (3.4 ± 1.4 %) within the CD34? CD45dim progenitor
cell gate, and observed a high level of DSG2 expression
within this EPC population (53.7 ± 13.6 % DSG2?;
Fig. 2a). Interestingly, these experiments also revealed that
DSG2 is expressed by VEGFR2-negative CD34?CD45dim
progenitor cells (41.6 ± 5.9 % DSG2?), the vast majority
of which are expected to be hematopoietic stem and pro-
genitor cells. Expression of DSG2 was also observed on
CD34? CD45dim progenitor cells in freshly isolated UCB,
with a trend towards higher expression compared to
peripheral blood (Fig. 2b). Given that DSG2 typically
combines with other desmosomal proteins [e.g., desmo-
collins (DSC1-3)] to form desmosomes between adjacent
cells [4], we also examined expression of the four other
desmosomal cadherins for which monoclonal antibodies
are commercially available. As shown in Fig. 2c, we were
unable to detect DSG1, DSG3, DSC2 or DSC3 (these latter
two are recognised by the same mAb) on CD34?CD45dim
progenitor cells in UCB, although as expected, DSG2 was
readily detectable. Further immunostaining revealed that
CD34?CD45dimDSG2? cells exhibited homogeneous
expression of CD31 and high levels of CD117 and CD133
expression, but very little expression of the mature
endothelial cell marker VE-cadherin (CD144) (Online
resources Supp. Figure 1). These data demonstrate that
circulating progenitor cells, including VEGFR2? EPCs,
express DSG2, but no other desmosomal cadherins,
suggesting a role for DSG2 in these cells independent of
desmosome function.
DSG2 expression in the hematopoietic lineage is
restricted to subsets of stem and progenitor cells
We showed in Fig. 2 that a large proportion of circulating
CD34?CD45dim cells express DSG2. While this population
includes cells with EPC activity [18, 38], it also harbours
major hematopoietic stem and progenitor cell subpopula-
tions. To assess DSG2 expression in early hematopoietic
development, normal human BM was stained with anti-
bodies against the stem/progenitor markers CD34, CD38,
CD90 and CD117. In CD34?CD45dim human BM pro-
genitors, DSG2 expression was highest and almost ubiq-
uitous on CD38-CD90? cells, which are thought to contain
the most primitive and long-term repopulating
hematopoietic stem cells [39] (Fig. 3a). A relative reduc-
tion in DSG2 expression was observed on CD38?CD90-
CD117? cells, with further reduction in CD38?CD90-
CD117- cells (Fig. 3a) indicating progressive loss of
DSG2 expression with increasing lineage commitment.
Investigation of myeloid lineages revealed DSG2
expression on common myeloid progenitors (CMP;
CD34?CD45dimCD117?CD33?CD13?) and on pro-mye-
locytes, in which CD34 is no longer expressed (CD34-
CD45dimCD117?CD33?CD13?) (Fig. 3b). DSG2 was also
observed on *40 % of pro-erythrocytes (CD34?
CD45dimCD117?CD71?CD235a-) and B cell lineage
progenitors, including pro-B cells (CD34?CD45dim
CD22?CD19-CD10-CD20-) (Fig. 3c, d).
For each of these lineages, DSG2 expression progres-
sively decreased as a function of differentiation and was
absent on all analysed mature cell types in the BM
(Fig. 3b–d). This is in keeping with our observations of
mature leucocyte populations in peripheral blood being
negative for DSG2 (CD3? T cells, CD14? monocytes,
CD16? NK cells and CD19? B cells) (Online resources
Supp. Figure 2). Interrogation of publically available
microarray data using the HemaExplorer tool [40] revealed
near perfect concordance with our analysis at the gene
expression level. Interestingly, further investigation
revealed that DSG2 gene expression correlates tightly with
expression of PROM1, which encodes the CD133 pro-
genitor marker (R2 = 0.92) as well as expression of CD34
(R2 = 0.60).
Using flow cytometric analysis, we also examined
expression of DSG2 on other stem cell populations and
observed that DSG2 was strongly and uniformly expressed
on three independently generated lines of induced
pluripotent stem (iPS) cells (Fig. 3e). Interestingly, the
parental fibroblast lines from which the iPS cells were
derived completely lacked DSG2 expression (Online
bFig. 3 Unique expression of DSG2 on immature hematopoietic
progenitor cells from human BM. Samples of normal human BM
were subject to erythrocyte lysis and stained for flow cytometric
analysis. In a, the expression of DSG2 in early hematopoietic
progenitor cell development was examined in CD34?CD45dim
progenitors by further gating on CD38-CD90?, CD38?CD90-
CD117? and CD38?CD90-CD117- subsets. In b, the expression of
DSG2 in myeloid development was examined by gating on
neutrophils (CD11b?CD13?CD33?CD16?CD117-); myelocytes
(CD11b?CD13?CD33?CD16-CD117-); pro-myelocytes (CD34-
CD117?CD45dimCD33?CD13?); CMP (common myeloid progen-
itors: CD34?CD117?CD45dimCD33?CD13?); pro-monocytes
(CD11b?CD13?CD45dimCD14-) and mature monocytes (CD11b
?CD13?CD33hiCD45brightCD14?). In c, the expression of DSG2
in erythrocyte development was examined by gating on pro-
erythroblasts (CD34?CD45dimCD117?CD71?CD235a-); ery-
throblasts (CD34-CD45-CD117-CD71?CD235a?) and erythro-
cytes (CD34-CD45-CD117-CD71-CD235a?). In d, the
expression of DSG2 in B cell development was examined by gating
on pro-B cells (CD34?CD45dimCD22?CD19-CD10-CD20-);
pre-BI cells (CD34?CD45dimCD22?CD19?CD10?CD20-); pre-
BII cells (CD34-CD45dimCD22?CD19?CD10?CD20±); imma-
ture B cells (CD34-CD45brightCD22?CD19?CD10?CD20bright)
and mature B cells (CD34-CD45brightCD22?CD19?CD10-
CD20bright). In e, expression of DSG2 on iPS cells but not DPSC
and MSCs was identified. Dots represent individual biological repli-
cates, except for MSCs wherein a cell line was repeatedly tested
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resources Supp. Figure 3). Also shown in Fig. 3e, three
independently generated lines of dental pulp stem cells
(DPSCs) and repeated measures of a MSC-like line
demonstrated that DSG2 was not expressed at
detectable levels by these progenitor cell types. Thus,
DSG2 is expressed by pluripotent stem cells but not by
stem cells with restricted mesenchymal differentiation
potential.
DSG21 progenitor cells expand in vitro and exhibit
multi-potent differentiation potential
To assess the functional capability of circulating DSG2?
progenitor cells, we isolated CD34?CD45dimDSG2? cells
and CD34?CD45dimDSG2- cells from UCB MNCs via
cell sorting. The purities of sorted cells were 97 ± 1 % for
DSG2? cells (Fig. 4a) and 89 ± 4 % for DSG2- cells.
Due to the low numbers (\1 9 104) of cells isolated in
these experiments, cells were expanded for 15 days in
defined growth medium [29] prior to further investigation.
While both DSG2- and DSG2? populations expanded
during culture, expansion was significantly greater in
DSG2? population at several time-points (Fig. 4b).
We next conducted cell fate analyses of the expanded
DSG2? versus DSG2- cell populations using methylcel-
lulose hematopoietic colony formation assays. DSG2?
cells cultured with GM-CSF, SCF, IL-3 and EPO for
14 days produced various colony types, including bi-potent
progenitors of the erythrocyte and myeloid lineages (CFU-
GEMM) and erythrocyte lineage (BFU-E) and granulo-
cyte/monocyte lineage (CFU-GM, CFU-G and CFU-M)
progenitors (Fig. 4c). Notably, the DSG2? cells generated
substantially more BFU-E and CFU-G colonies compared
to DSG2- cells (Fig. 4c). Similarly, freshly isolated,
unexpanded DSG2? cells purified from fresh human adult
BM gave rise to significantly more BFU-E, CFU-G and
CFU-M colonies compared with freshly isolated, unex-
panded DSG2- cells (Fig. 4d). These findings suggest that
CD34?CD45dimDSG2? hematopoietic progenitor cells
have multi-lineage differentiation potential and enhanced
colony formation capacity compared to their DSG2-
counterparts.
We next examined the capacity of the DSG2? sorted
cells to promote endothelial tube-like formation using
Matrigel [22, 29]. HUVEC were seeded either alone or
after mixing with expanded DSG2? cells, and the forma-
tion of capillary-like networks was monitored over a 6 h
period. Quantitation of vessel formation identified a sig-
nificant increase in the number of tube-like structures from
HUVEC in the presence of DSG2? cells, suggesting that
DSG2? cells are pro-angiogenic (Fig. 4e). As expected
from their immature phenotype, DSG2? cells were unable
to form tubes in the absence of HUVEC (data not shown).
Heterogeneous expression of DSG2 in mature ECs
in vivo
Results thus far suggest that DSG2 is expressed by freshly
isolated as well as short-term-cultured EPCs and that
DSG2? progenitor cells have pro-angiogenic activity
in vitro. Based on these findings, we examined whether
DSG2? cells were present in mature endothelium. To
address this, a human tissue microarray with multiple cores
of 30 normal and 38 cancerous tissues was examined
morphologically for the presence of DSG2 on red blood
cell-containing lumenised blood vessels. We identified
vessels in 16 normal tissues and 13 tumours (Online
resources Supp. Table 2). For the normal tissues, 8/16
(50 %) contained vessels with DSG2? ECs in at least one
of three stained sections per tissue, while all vessels in the
other tissues lacked detectable DSG2 expression. In
cancerous tissues, 7/13 tumour specimens (54 %) con-
tained DSG2? vessels (Online resources Supp. Table 2).
To note, immunohistochemistry on human cervix tissue
from a healthy individual revealed that DSG2 can be
expressed by the endothelium of both arterioles (Fig. 5a,
arrow head) and venules (Fig. 5a, arrow). To further con-
firm the expression of DSG2 by vascular ECs, multi-colour
immunofluorescence microscopy was performed after co-
staining sections for DSG2 and CD31. This identified
heterogeneous expression of DSG2 in ECs in normal
human cervix, with both CD31?DSG2? (Fig. 5b, top left
and top middle panels) and CD31?DSG2- (Fig. 5b, bot-
tom left and bottom middle panels) vessels evident.
bFig. 4 Enrichment of DSG2? progenitor cells demonstrate a pro-
proliferative and multi-potential nature. In a, samples of UCB were
sorted for DSG2? and DSG2- subsets. Pre-sorted CD34?CD45dim-
gated cells were stained for IgG control (far left panel) and DSG2
(middle left panel), and compared to the DSG2 staining amongst post-
sort DSG2? (middle right panel) and DSG2- (far right panel) cells.
In b, DSG2? and DSG2- cell expansion was calculated over
15 days. Results are mean ± SEM, n = 3 donors, *p\ 0.05. In c,
expanded UCB-derived DSG2? and DSG2- cells and in d, freshly
sorted BM-derived DSG2? and DSG2- cells were seeded for colony
formation. Cells formed blast-forming unit-erythroid (BFU-E),
colony-forming units (CFU)-GEMM, -GM, -G and -M colonies.
Results are mean ± SEM, n = 3–4 donors, *p\ 0.05 compared to
DSG2- cells. In e, a representative image of the Matrigel angiogen-
esis assay performed with HUVEC alone (upper image) or HUVEC
co-cultured with DSG2? sorted and expanded UCB cells (lower
image) in vitro. Relative tube-like structure numbers formed in each
condition from 3 independent experiments are quantified on the right
as mean ± SEM, *p\ 0.05 versus HUVEC alone. Scale bar is
20 lm
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In silico analysis of publically available microarray data
revealed that Dsg2 is also heterogeneously expressed by the
mouse vasculature. In a recent study, Lee and colleagues
generated whole genome expression data from lymphoid
tissue-derived ECs isolated from either high endothelial
venules (HEV) or capillaries (GSE58056) [41]. Our
Fig. 5 Mature ECs display
heterogeneous expression of
DSG2. In a, representative IHC
images of human cervical tissue
with positive brown staining for
DSG2 (centre panel) wherein an
arteriole (arrow head) and a
venule (arrow) are shown. The
same tissue area is also shown
stained separately with H&E,
allowing visualisation of vessel
architecture (right panel).
Isotype control staining of
cervical tissue (left panel). Scale
bar is 0.2 mm. In b,
representative
immunofluorescence images of
human cervical tissue with
DSG2 (red), CD31 (green) and
DAPI (blue) illustrate a DSG2?
vessel (top left and middle) and
a DSG2- vessel (bottom left and
middle). Staining controls on the
right show the same cervical
tissue with relevant isotype
controls (top right; negative
control) and cervical epithelium
(bottom right; positive control).
Scale bar is 30 lm. In c, gene
expression values (EV) of
Dsg1–3 and Dsc1–3 mined from
GEO dataset GSE58056. Each
symbol represents an individual
biological replicate from
capillary or high endothelial
venules (HEV); small horizontal
lines indicate the mean,
*p\ 0.05 versus capillary.
(Color figure online)
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interrogation of this data using GEO2R revealed signifi-
cantly elevated levels of Dsg2 in the HEV-derived ECs
compared to capillary-derived ECs from the lymphoid tissue
(Fig. 5c). No difference in expression was observed for other
desmosomal cadherins (Dsg1&3 and Dsc1-3) (Fig. 5c).
Generation of Dsg2lo/lo mice
To study DSG2 function in vivo, we generated a ‘knock-
out-first’ Dsg2 mouse strain on a C57BL/6 N background.
This ‘gene trap’ approach utilised a targeted insertion of an
FRT-flanked lacZ-neomycin cassette into intron 1 of the
murine Dsg2 locus (see schematic of the inserted cassette
in Fig. 6a). Mice heterozygous for insertion of the lacZ-
neomycin construct were inter-bred and yielded fertile
wildtype (WT), heterozygous and homozygous offspring at
the expected Mendelian ratios (1:2:1), with litter sizes
similar to WT C57BL/6N controls.
Upon examination of Dsg2 gene expression in these
mice, we observed a significant reduction in Dsg2 mRNA
in the heart (where Dsg2 is strongly expressed [42]) in
heterozygous and homozygous mice compared to WT mice
(Fig. 6b), indicating perturbed Dsg2 transcription with this
‘knockout-first gene trap’ approach. Similar results were
observed in the skin (data not shown). This observation of
reduced Dsg2 expression in the heart prompted us to
examine for cardiac fibrosis, a previously reported pheno-
type of Dsg2-knockout mice [5, 43] and humans with
DSG2 mutations [3, 6]. In dissected hearts of the
homozygous mutant mice, fibrotic lesions were frequently
seen in the enlarged hearts (Fig. 6c, arrow). Fibrotic lesions
were confirmed by histological analysis using a hema-
toxylin/eosin stain with an arrow identifying a fibrotic
lesion (Fig. 6d). Notably, this pathology was less evident in
the heterozygous mice (Fig. 6c, d). We thus concluded that




























Fig. 6 Disruption of intron 1 of Dsg2 results in a hypomorphic DSG2
allele. In a, a lacZ/neomycin cassette was incorporated into intron 1 of
mouse Dsg2 by targeted insertion. b The resulting Dsg2-LacZ-
neomycin allele exhibited reduced Dsg2 expression in the mouse
hearts of WT, Dsg2?/lo and Dsg2lo/lo mice by quantitative PCR
(qPCR). Results are mean ± SEM, n = 3, *p\ 0.05 versus WT. In
c, morphological comparison of hearts from WT, DSG2?/lo and
Dsg2lo/lo mice with arrows identifying fibrotic lesions. Scale bar is
3 mm. In d, dissected hearts stained with hematoxylin/eosin and an
arrow identifying fibrotic lesions. Scale bar is 0.5 mm
Angiogenesis (2016) 19:463–486 475
123
Dsg2lo) which resulted in normal viability and fertility and
is in contrast to the embryonic lethality observed in the
Dsg2-knockout mice detailed in Eshkind et al. [44]. Based
on these observations, we reasoned that our Dsg2 line
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A role for DSG2 in neoangiogenesis
A gross comparison of the development and patterning of
blood and lymphatic vessels in adult skin was then con-
ducted in the ears of adult WT and Dsg2lo/lo mice via whole
mount immunostaining using markers to blood (CD31?)
and lymphatic (CD31? LYVE-1?) vascular ECs. As shown
in Fig. 7a, no overt differences in the macroscopic pat-
terning of either vessel type were observed in Dsg2lo/lo
mice. However, microscopic examination of the ECs
within a cross section of pancreatic vessels suggested
otherwise. As shown in Fig. 7b, high magnification images
revealed morphological abnormalities of CD31? ECs in the
Dsg2lo/lo mice, including regions of increased junctional
hypertrophy and an undulating luminal surface. Analysis of
EC width using Image J revealed that the vascular wall
width of the Dsg2lo/lo mice was significantly greater than
that of the control mice. To visualise perivascular cells
associated with the blood vasculature, we examined aSMA
expression using immunohistochemistry. Image J analysis
of the SMA staining patterns failed to detect any differ-
ences between the WT and Dsg2lo/lo mice, suggesting no
alteration in vessel contractility (Fig. 7c).
As CD34?CD45dimDSG2? cells displayed a pro-an-
giogenic phenotype in vitro (Fig. 4e), we interrogated this
further using ECs obtained from Dsg2lo/lo mice. First, we
compared the ability of BM-derived EPCs from WT and
Dsg2lo/lo mice to form endothelial colonies on fibronectin-
coated culture dishes [32]. As shown in Fig. 8a, BM-
derived ECs from Dsg2lo/lo mice were smaller in colony
size and lower in total colony number when compared to
WT controls. Consistent with this, BM-derived ECs from
Dsg2lo/lo mice showed reduced formation of tube-like
structures on Matrigel compared with BM-derived ECs
from WT mice (Fig. 8b). We also compared WT and
Dsg2lo/lo mice for their ability to generate endothelial
sprouts in an aortic ring assay [33]. The top left image of
Fig. 8c demonstrates that aortic rings from WT mice
generate sprouts in response to VEGF, and the top right
image of Fig. 8c confirmed that the sprouts were CD31?
ECs. Notably, the lower panels of Fig. 8c and the quan-
tified data in the graph illustrate that Dsg2lo/lo mice pro-
duced significantly fewer vascular sprouts in response to
VEGF compared to aortic rings from WT mice. Next,
neoangiogenesis was tested in vivo by injection of a
Matrigel bolus into the flanks of WT and Dsg2lo/lo mice,
followed 7 days later by immunohistochemical examina-
tion of excised plugs for evidence of angiogenic sprout-
ing. While plugs from WT mice contained numerous
erythrocyte-containing CD31? vessels, these were largely
absent in plugs from Dsg2lo/lo mice (Fig. 8d). Finally, we
translated this into a more clinically relevant in vivo
model by examining the vasculature of B16 melanomas in
the WT and Dsg2lo/lo mice. At approximately 20 days
post-injection, immunohistochemical examination of
excised tumours showed that tumours from WT mice
contained significantly more CD31? vessels than the
tumours in the Dsg2lo/lo mice (Fig. 8e).
Knockdown of DSG2 in human ECs suggests a role
in EC barrier integrity, adhesion and migration
Using flow cytometry, we identified DSG2 expression in a
subpopulation of cells present in the human BM-derived
EC line TrHBMEC (BMEC) [45] (Fig. 9a). To investigate
a role for DSG2 in EC function, we sorted for this DSG2?
subpopulation (Fig. 9a), resulting in a culture which was
95 % DSG2? immediately after sorting and maintained
similar levels of DSG2 expression for several passages.
DSG2 gene knockdown was performed on these cells,
resulting in significant reductions in DSG2 surface protein
using three different siRNA constructs (Fig. 9b). Using
annexin V, 7-AAD and flow cytometry, we compared
BMEC cell viability 72 h post-knockdown of DSG2 and
observed a similar percentage survival rate of 84 ± 5 for
the control siRNA cells compared to 74 ± 6, 87 ± 3 and
79 ± 4 for siRNA-A, siRNA-B and siRNA-C, respec-
tively. Next, we tested the function of DSG2-reduced
BMEC cells in a Matrigel angiogenesis assay and observed
a significant reduction in the number of tube-like structures
for all three DSG2-targeting siRNA constructs when
compared to the cells transfected with control siRNA.
Figure 9c illustrates a representative image of tube-like
structures formed as well as the quantitation from three
separate experiments. Interestingly, close examination of
the cells in this angiogenesis assay suggested that depletion
of DSG2 prevented them from elongating, as they
remained round in shape (Fig. 9c, enlarged insert). As actin
filaments of the cytoskeleton are important components
which control dynamic processes such as cell shape, cell–
bFig. 7 Dsg2lo/lo mice exhibit altered EC morphology. In a, a
representative image of blood (CD31, green) and lymphatic
(LYVE-1, blue) vessels in mid-ear sections of WT and Dsg2lo/lo
adult mice with aSMA shown in the merged image (red). In b,
representative fluorescence images of CD31? ECs (yellow) in
pancreatic sections of control (WT) and Dsg2lo/lo mice, with DAPI
nuclei staining (blue), scale bar is 50 lm. The graph shows analysis
of EC width (measured in 6 positions per vessel) from five vessels per
mouse. Results are mean ± SEM, n = 3 mice/group, *p\ 0.05
versus WT. In c, representative fluorescence images of pancreatic
sections of control (WT) and Dsg2lo/lo mice, with CD31? ECs
(green), aSMA perivascular cells (red) and DAPI nuclei staining
(blue). Scale bar is 0.1 mm. The graph shows analysis of vessel width
(measured in 6 positions per vessel) from five vessels per mouse.
Results are mean ± SEM, n = 4 mice/group. (Color figure online)
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cell adhesion and cell migration (reviewed in [46]), we
next investigated whether alteration of DSG2 affected actin
assembly in ECs. Using the aforementioned siRNA
knockdown approach and immunofluorescence staining for
VE-cadherin to define cell borders, we observed that the
actin filament-containing structures differed significantly
when DSG2 was reduced. As shown in Fig. 9d, control
cells showed junction-associated circumferential phalloidin
stained actin filaments (cortical actin), while the DSG2-
reduced BMEC cells exhibited cytoplasmic stress fibres.
Quantitation of the amount of actin localised to the cell
boundary (i.e., cortical) versus that covering a cell (i.e., in
stress fibre formation) revealed that for all three DSG2-
targeting siRNA constructs, a significant increase in stress
fibre content was observed (Fig. 9e). Further examination
with ImageJ confirmed that DSG2 knockdown significantly
increased actin assembly into stress fibre formation, as
reflected by an increase in the total area of phalloidin
staining (Fig. 9f).
As stress fibre formation is often accompanied by
actin-mediated contraction and remodelling of the VE-
cadherin complex from a continuous to an interrupted
patterning [47, 48], we next investigated whether VE-
cadherin localisation was also affected by DSG2 knock-
down. Figure 10a shows that in control cells VE-cadherin
is tightly maintained within the adherens junctions, while
knockdown of DSG2 reorients VE-cadherin into dis-
jointed and perpendicular adhesions. Quantitation of VE-
cadherin fluorescence intensities along cell junction lines
(depicted by the opaque box overlay the enlarged images
of Fig. 10a) supported this observation with VE-cadherin
in control cells contained within the termini of short
bundles while in the DSG2 knockdown cells was irreg-
ular in intensity. These observations, together with those
in the aortic ring assay (Fig. 8c), prompted us to test the
cell–cell interactions in an adhesion assay. Briefly,
BMEC cells transfected with control or DSG2-targeting
siRNAs were seeded into two culture dishes, and after
72 h one dish was trypsinised into a single-cell suspen-
sion and stained with calcein-AM, while the second
remained as a confluent monolayer. The calcein-labelled
BMEC (±DSG2-siRNA) were incubated with the BMEC
monolayers (also ±DSG2-siRNA) for 15 min to permit
adhesion prior to stringent washing to remove any
unbound cells. The left panel of Fig. 10b shows a rep-
resentative image of calcein-labelled adherent BMEC
cells (±DSG2-siRNA) using fluorescence microscopy,
while the graph shows quantitation from three separate
experiments wherein a significant reduction in bound
fluorescent cells following DSG2 knockdown was
observed. This data therefore suggest that DSG2 plays a
critical role in regulating cell–cell adhesion between
human mature ECs. To investigate whether DSG2 con-
tributed to EC invasion, we conducted inverse invasion
assays wherein BMECs (±DSG2-siRNA) penetrated
through an extracellular matrix (Matrigel) towards a
chemoattractant (VEGF). Interestingly, BMEC with
reduced DSG2 exhibited greater invasive potential by
being able to migrate further through the Matrigel matrix
and towards VEGF (Fig. 10c, representative image).
Quantitation of cell number relative to distance travelled
confirmed that all three DSG2-targeting siRNA con-
structs significantly enhanced the number of cells
invading into the Matrigel as well as their distance
travelled (Fig. 10c).
Discussion
This study reveals that, in addition to epithelial cells and
cardiomyocytes, DSG2 is also expressed on sub-popula-
tions of human blood and BM-derived progenitor cells. We
also provide multiple lines of evidence that DSG2 is
expressed by cells of the endothelial lineage and that it
contributes to neoangiogenesis. Our findings provide crit-
ical new information that DSG2 is much more than a
simple desmosomal adhesion molecule.
In their canonical role, the Ca2?-binding transmem-
brane glycoprotein desmosomal cadherins DSG1-4 and
DSC1-3 associate to form homotypic and heterotypic
interactions with adjacent cells, resulting in specialised
junctions designed to withstand mechanical stress in the
myocardium and stratified epithelium [3, 4]. Here we have
bFig. 8 Dsg2lo/lo mice exhibit reduced vascular development. In a,
BM-derived EC colonies were generated from WT and Dsg2lo/lo mice
by culture on fibronectin plates for 6 days. Images on the left show
representative colonies, while the graph on the right depicts the
number of colonies per well (mean ± SEM, n = 3, *p\ 0.05 versus
WT, scale bar is 0.2 mm). b shows BM-derived ECs from WT and
Dsg2lo/lo mice seeded onto Matrigel. Tube-like structure formation
captured by phase-contrast microscopy 4 h post-seeding. Results are
mean ± SEM, n = 3, *p\ 0.05 versus WT. Scale bar is 0.2 mm. In
c, phase-contrast images of aortic rings embedded in Matrigel
showing microvessel outgrowth in response to VEGF (top left, scale
bar is 0.5 mm); CD31 staining of the vascular sprouts (top right, scale
bar is 0.1 mm); and sprouts counted 5 days post embedding. Higher
magnification of rings shown for WT (bottom left) and Dsg2lo/lo
(bottom right). Results are mean ± SEM, n = 3, *p\ 0.05 versus no
VEGF, # p\ 0.05 versus WT ? VEGF. In d, Matrigel plugs in WT
and Dsg2lo/lo mice were retrieved and stained with anti-CD31 (brown)
and hematoxylin (lilac). Scale bar is 50 lm. The number of
erythrocyte-containing vessels per mm2 was quantified. Data
expressed as mean ± SEM, n = 5–10, *p\ 0.05 versus WT. In e,
B16 melanomas in WT and Dsg2lo/lo mice were retrieved and stained
with anti-CD31 (red) and eosin (blue). Scale bar is 100 lm. The
average number of CD31? vessels per field of view was quantified.
Data expressed as mean ± SEM, n = 7, *p\ 0.05 versus WT
(Mann–Whitney). (Color figure online)
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uncovered an additional role for DSG2, in non-desmo-
some-forming progenitor cells and endothelial cells. We
first identified DSG2 as a highly expressed gene and cell
surface protein on human EPCs. Further investigation
revealed that DSG2 is also expressed on the closely related
hematopoietic progenitor cell lineage, being detectable on
early hematopoietic progenitors, common myeloid pro-
genitors, pro-erythroblasts and pro-B-cells, but not on the
more differentiated progenitors or mature leucocyte sub-
sets. Our observation of a tight correlation between DSG2,
CD133 and CD34 genes suggests that DSG2 may play an
important, as yet unidentified, role in symmetric cell
division and progenitor renewal. CD34 is the classical
marker of hematopoietic progenitors and contributes to cell
adhesion and hematopoietic differentiation [49]. BM-
derived CD34? cells reconstitute hematopoietic cells [50]
and CD34 is also expressed by EPCs and mature ECs
[22, 51]. CD133 is also a marker of hematopoietic stem and
progenitor cells (HSPCs) and is restricted to*20–60 % of
the CD34? cells isolated from adult BM, UCB or periph-
eral blood [52], and the CD133?CD34? fraction of HSPCs
has a high capacity for expansion [53]. We demonstrate
that DSG2 is expressed almost ubiquitously by CD133?
cells and at highest levels by the CD38-CD90? subset.
Thus, our study identifies DSG2 as a new cell surface
marker for the most primitive and proliferative of HSPCs.
In data also shown here, we observed that DSG2 is
expressed by induced pluripotent (iPS) cells, which sup-
ports our contention of this cadherin being a marker of
progenitor cells and extends a previous publication of
DSG2 being one of the early activated genes in the
reprogramming of fibroblasts to iPS cells [54]. Based on
these findings, we propose that DSG2 is a new, and
potentially useful, marker of primitive HSPCs and we
speculate that it may influence their proliferation and sur-
vival. One intriguing possibility is that DSG2 on the sur-
face of HSPCs undergoes homotypic interactions with
DSG2 expressed by ECs within the BM, thereby con-
tributing an adhesive and/or signalling function within this
established stem cell niche [55].
The studies presented here also provide clear evidence
that DSG2 is expressed uniformly by EPCs and by some
mature ECs and that it regulates neoangiogenesis. First, we
showed that DSG2 is expressed by an enriched population
of non-adherent EPCs as well as freshly isolated CD34?-
CD45dimVEGFR2? EPCs from blood. This finding is
supported by the recent work of Patsch et al. [56] who
converted human pluripotent stem cells into functional ECs
and investigated their transcriptional gene signature. Our in
silico analysis of this publically available gene expression
array confirms that human ES cells express DSG2 and
reveals that this gene remains detectable, albeit to a lesser
extent, in the transformed ECs (data not shown). Further
interrogation of the endothelial lineage revealed that, while
HUVEC are uniformly negative for DSG2, the human BM
EC line (TrHBMEC) contains a distinct subpopulation that
is DSG2 positive. This is consistent with our observations
in normal human and cancerous tissues where, by
immunohistochemistry and immunofluorescence, we
detected DSG2 on some but not all blood vessels. Notably,
we were able to detect DSG2 on both arterioles and venules
and this is supported by our in silico analysis of the gene
expression array conducted by Aranguren et al. [57]
wherein we were able to detect DSG2 in both arterial and
venous ECs (data not shown). Interestingly, expression of
DSG2 within this cohort also varied across samples which
supports our observation of differential expression of this
cadherin by vascular ECs. Heterogeneity was also observed
amongst mouse ECs when we performed an in silico
analysis of a recent publication by Eugene Butcher’s lab-
oratory, wherein a gene expression analysis was conducted
on ECs isolated from mouse lymphoid organ HEVs and
capillaries [41]. In support of our contention that certain
ECs can express DSG2, Giusti et al. have also reported
DSG2 expression by skin microvascular ECs [58]. It is
tempting to speculate that DSG2 is expressed by newly
formed vasculature, but the molecular basis underlying
differential expression of DSG2 on ECs is yet to be elu-
cidated and is part of ongoing studies within our laboratory.
bFig. 9 DSG2 knockdown alters BMEC function and cytoskeletal
composition. In a, BMEC cells were sorted for DSG2? and DSG2-
subgroups. Results show pre-sort cells stained for control IgG (far left
panel) or DSG2 (middle left panel), and compared to the DSG2
staining amongst post-sort DSG2?(far right panel) and DSG2-
(middle right panel) cells. In b, the sorted DSG2?BMEC cells were
subject to DSG2 knockdown using siRNA and analysed for DSG2
protein expression via flow cytometry after 72 h. Histogram shows
staining with control IgG (red), or DSG2 after treatment with non-
targeting control siRNA (blue) or DSG2-targeting siRNA-A (dotted
black). The graph shows DSG2 expression quantified as mean
fluorescence intensity (MFI). In c, representative images of the effect
of DSG2 knockdown on tube-like structure formation by sorted
DSG2 ? BMEC cells after 6 h on Matrigel are shown on the left
(scale bar is 0.2 mm), while the number of tube-like structures
formed per well was quantified on the right. Data expressed as
mean ± SEM, n = 6, *p\ 0.05 versus control siRNA. In d,
representative images of the effect of DSG2 knockdown on the
localisation of actin (phalloidin, far left) and VE-cadherin (middle)
and merged image (far right (phalloidin (red) and VE-cadherin
(green)) are shown. Scale bar is 20 lm. In e, stratification of actin
localisation via phalloidin staining of cortical or stress fibre formation
for individual cells (defined by DAPI-stained nucleus) and normalized
to control siRNA cells within an experiment. Data expressed as
mean ± SEM, n = 3, *p\ 0.05 versus control siRNA. In f, ImageJ
was used to quantify the area of phalloidin staining relative to the
number of nuclei per field of view and normalized to control siRNA
cells within an experiment. Data expressed as mean ± SEM, n = 3,
*p\ 0.05 versus control siRNA. (Color figure online)
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A role for DSG2 in the vasculature is supported by our
‘loss-of-function’ Dsg2lo/lo mice which show that Dsg2
promotes BM-derived EPC colony formation, ex vivo
vascular sprouting and formation of vessel-like structures
in vitro and in vivo. These Dsg2lo/lo mice were generated
using a ‘knockout-first allele’ strategy which ablates gene
function by insertion of a cassette into an intron of the
intact gene and produces a knockout at the RNA processing
level. This strain produced viable and fertile homozygous
mice which displayed reduced, but not completely absent,
levels of Dsg2; thus, our mice were termed Dsg2 ‘hypo-
morphs’. The Dsg2lo/lo mice described herein are compa-
rable to those generated by Krusche et al. [43] who
obtained largely fertile Dsg2-knockout mice but are dis-
tinct from the Dsg2-knockout mice published by Eshkind
et al. [44], which were embryonic lethal at the time of
blastocyst implantation. Importantly, the cardiomyopathy
observed in the Krusche et al. [43] mice, characterised by
fibrotic lesions in the heart, was also evident in our strain of
Dsg2lo/lo mice and is in keeping with the human clinical
condition associated with DSG2 ‘loss-of-function’,
arrhythmogenic right ventricular cardiomyopathy/dysplasia
(ARVC) [5, 6]. Fundamental differences between these
three Dsg2 ‘loss-of-function’ mice warrant further expla-
nation; Eshkind et al. substituted exons 7 and 8 of the Dsg2
gene with a cassette conferring lacZ expression and neo-
mycin resistance in C57BL/6 and 129/Sv mouse strains,
while Krusche et al. [59] utilised a targeting construct for
inducible deletion of exons 4–6 in C57BL/6J mice. Our
Dsg2lo/lo mice differ again in that construct insertion is
characterised by an in-frame intronic insertion between
exons 1 and 2 on the C57Bl/6N background. It is possible
that the positioning in intron 1 disrupts an enhancer region,
resulting in ‘loss-of-function’, as has been documented for
the epithelial cadherin (E-cadherin). To note, Eshkind et al.
[44] demonstrated that the lethality of Dsg2 depletion is
influenced by genetic background of the mice, with 129/Sv
mice displaying a higher lethality than the C57BL/6 strain.
Historically, studies of DSG2 function have focused on
its role in desmosomes, with important clinical implica-
tions for understanding the pathogenesis of cardiac disease
with increasing reports of dominantly inherited frameshift,
splice site, nonsense and missense mutations of DSG2
(mostly in the extracellular domain) in sudden death from
ARVC as well as sudden unexplained death [60–62]. A
recent study by Kant et al. showed that mice with car-
diomyocyte-specific Dsg2 ablation lack desmosome-like
structures in the heart and that other desmosomal cad-
herins, e.g., Dsc2, are unable to fully compensate for the
loss of Dsg2 [63]. However, with the identification of
DSG2 on several normal and cancerous cell types that
completely lack desmosomes [44, 64], there is increasing
evidence for pleiotropic functions of this desmosomal
cadherin. For example, Nava and colleagues demonstrated
in intestinal epithelial cells that proteolytic cleavage of an
intracellular fragment of DSG2 caused an increase in cas-
pase 3 activation, cleavage of poly(ADP-ribose) poly-
merase (PARP) and cell apoptosis [65]. Brennan et al. also
observed that overexpression of DSG2 in suprabasal ker-
atinocytes induced hyperproliferation, resistance to anoikis
and enhanced carcinogenesis [66]. Reports also document
‘non-junction-bound’ DSG2 on epithelial cells and cancer
cells where it provides additional biological roles including
regulation of apoptosis [65], proliferation [66, 67] and
vasculogenic mimicry in melanoma [68]. Whether such
effects are primary (a direct consequence of the change in
DSG2 expression) or secondary (a response to changes in
cell adhesion) is not certain. However, the ProteinPredict
program of ExPASy indicates many potential protein
kinase C (PKC)-target motifs exist in DSG2, including 13
in the cytoplasmic domain [69], and epidermal growth
factor treatment of A431 epithelial cells induces tyrosine
phosphorylation of DSG2 [70]. Moreover, the aforemen-
tioned Brennan et al. study of suprabasal expression of
DSG2 in keratinocytes activated multiple pathways,
including PI3K/Akt, MAPK/ERK, STAT3 and NFjB [66].
Thus, multiple lines of evidence suggest that DSG2 may
contribute to intracellular signalling events in addition to
its established role in cell adhesion.
In addition to the well-recognised link between DSG2
mutation and cardiomyopathy in humans, a second clinical
manifestation linked to DSG2 loss-of-function has been
identified in patients with systemic sclerosis (SSc, sclero-
derma). These patients exhibit insufficient angiogenesis in
connective tissues, which is associated with a reduction in
DSG2 expression in microvascular ECs [58]. This
bFig. 10 DSG2 knockdown alters BMEC cell junction formation,
adhesion and invasion. In a, representative images of the effect of
DSG2 knockdown on the localisation of VE-cadherin (green) with
DAPI-stained nuclei (blue) are shown. Scale bar is 20 lm. Accom-
panying fluorescence intensities along the depicted lines depict
localisation of VE-cadherin along a cell–cell junction. In b, the
adhesion of fluorescently labelled BMEC cells to a confluent
monolayer of unlabelled BMEC cells was determined using sorted
DSG2 ? BMEC cells treated with the indicated siRNA. Represen-
tative fluorescent images are shown on the left (scale bar is 0.2 mm),
while the number of adherent cells per field of view was quantified on
the right. Results are shown as mean ± SEM, n = 3–5, *p\ 0.05
versus control siRNA. In c, BMEC treated with control or DSG2-
targeting siRNA for 24 h were allowed to invade Matrigel covered
Transwells in an inverse invasion assay. Scale bar is 0.4 mm. After
four days of invasion, cells were stained with propridium iodide and
serial optical sections (6.68-lm intervals) were acquired. Magnified
images from z = 22 sections are shown (top). Cell invasion was
quantified as the number of cells over distance travelled and then
normalised to peak control siRNA values for each experiment. Data
show mean ± SEM, n = 6, p\ 0.05, ANOVA. (Color
figure online)
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observation supports our contention that DSG2 regulates
EC function and angiogenesis. The precise role for DSG2
in systemic sclerosis and angiogenesis is still unclear, with
recent evidence suggesting impaired actin assembly and
correlation with integrin b8 complex formation [71].
Interestingly, our observations contradict this study as we
demonstrate that that loss of DSG2 by ECs induces stress
fibre formation rather than impairing it. An important point
of difference between these two studies is that we exam-
ined actin assembly in a confluent monolayer of ECs, while
their coverage of ECs is clearly subconfluent, likely
impacting on overall response and outcome. Herein we also
show that loss of DSG2 by ECs interrupts VE-cadherin
patterning within adherens junctions and culminates in a
phenotype with heightened invasion through an extracel-
lular matrix. Our adhesion assays suggest, for the first time,
that DSG2 associates to form homotypic interactions
between adjacent ECs, which form junctions designed to
support vascular development. This is supported by docu-
mentation of DSG2–DSG2 interactions within the desmo-
some complex occurring via the ‘cell adhesion recognition’
(CAR) site. This conserved YAL sequence within the
adhesive interface is located within the first of four extra-
cellular repeat domains at the N-terminus of DSG2 and
10-mer peptides targeting this site have proven effective in
their inhibition of epithelial cell interactions [72].
This study has revealed, for the first time, DSG2
expression in distinct progenitor cell subpopulations and
shows that, independent from its canonical role as a com-
ponent of desmosomes, this cadherin also plays a critical
role in the vasculature. Because of this work, continued
investigation of DSG2-mediated biology in EPCs and ECs,
including the intercellular adhesive events, will undoubt-
edly provide further insight into the pathogenesis of vas-
cular disease and the potential of manipulation of DSG2 for
therapeutic use.
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